Literature DB >> 8568287

Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly.

G J Gorse1, E E Otto, D C Powers, G W Chambers, C S Eickhoff, F K Newman.   

Abstract

Induction of local antibody responses to influenza A virus hemagglutinin by coadministration of two vaccines was investigated. Fifty elderly nursing home residents received inactivated trivalent influenza virus vaccine intramuscularly and simultaneously were randomized to receive either bivalent live attenuated influenza A virus vaccine or saline placebo intranasally in a blinded fashion. More significant increases in anti-H1 and -H3 IgA antibodies were detectable in nasal wash specimens of subjects who received live attenuated virus vaccine than in those who received intranasal placebo. The increased anti-hemagglutinin IgA antibody response was of longer duration in recipients of live attenuated vaccine. The change in antibody titers after vaccination was positively correlated with total blood lymphocyte counts measured before vaccination in both vaccinee groups (P < .05). There was a possible advantage of administering live attenuated with inactivated virus vaccines because of enhanced local antibody responses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8568287     DOI: 10.1093/infdis/173.2.285

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  18 in total

1.  Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts.

Authors:  Boris Ferko; Christian Kittel; Julia Romanova; Sabine Sereinig; Hermann Katinger; Andrej Egorov
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

2.  Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina.

Authors:  C Bergquist; E L Johansson; T Lagergård; J Holmgren; A Rudin
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

3.  Anti-influenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected children.

Authors:  Adriana Weinberg; Lin-Ye Song; Robert Walker; Maria Allende; Terence Fenton; Julie Patterson-Bartlett; Sharon Nachman; George Kemble; Ting-Ting Yi; Patricia Defechereux; Diane Wara; Jennifer S Read; Myron Levin
Journal:  J Acquir Immune Defic Syndr       Date:  2010-10       Impact factor: 3.731

4.  Genetically engineered live attenuated influenza A virus vaccine candidates.

Authors:  N T Parkin; P Chiu; K Coelingh
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

5.  Seasonal trivalent inactivated influenza vaccine protects against 1918 Spanish influenza virus infection in ferrets.

Authors:  Melissa B Pearce; Jessica A Belser; Kortney M Gustin; Claudia Pappas; Katherine V Houser; Xiangjie Sun; Taronna R Maines; Mary J Pantin-Jackwood; Jacqueline M Katz; Terrence M Tumpey
Journal:  J Virol       Date:  2012-05-02       Impact factor: 5.103

6.  Prevalence of antibodies to four human coronaviruses is lower in nasal secretions than in serum.

Authors:  Geoffrey J Gorse; Gira B Patel; Joseph N Vitale; Theresa Z O'Connor
Journal:  Clin Vaccine Immunol       Date:  2010-10-13

Review 7.  Intranasal cold-adapted influenza virus vaccine combined with inactivated influenza virus vaccines: an extra boost for the elderly?

Authors:  Paul V Targonski; Gregory A Poland
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

8.  Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children.

Authors:  Myron J Levin; Lin-Ye Song; Terrence Fenton; Sharon Nachman; Julie Patterson; Robert Walker; George Kemble; Maria Allende; Micki Hultquist; Tingting Yi; Barbara Nowak; Adriana Weinberg
Journal:  Vaccine       Date:  2008-06-10       Impact factor: 3.641

9.  Impact of prior seasonal H3N2 influenza vaccination or infection on protection and transmission of emerging variants of influenza A(H3N2)v virus in ferrets.

Authors:  Katherine V Houser; Melissa B Pearce; Jacqueline M Katz; Terrence M Tumpey
Journal:  J Virol       Date:  2013-10-02       Impact factor: 5.103

Review 10.  Respiratory syncytial virus vaccines.

Authors:  R A Dudas; R A Karron
Journal:  Clin Microbiol Rev       Date:  1998-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.